Key points
- FDA will hold a roundtable on Feb. 10, 2026 (9 a.m.–5 p.m. ET) with small tobacco product manufacturers (<350 employees).
- The session will solicit input on PMTA submissions for ENDS products and will be available to view online.
- Topics include PMTA components: product characterization, manufacturing controls, pharmacological profile (e.g., PK studies), adult benefit studies (e.g., cohort/RCT), and toxicological profile (e.g., lifetime cancer risk estimates).
- FDA opened a public comment docket; electronic comments are due by 11:59 p.m. ET on March 12, 2026 via Regulations.gov.
2Firsts, Feb 10, 2026
According to the U.S. Food and Drug Administration (FDA), the agency issued a Federal Register notice on Dec. 23, 2025 announcing a roundtable discussion with small tobacco product manufacturers (fewer than 350 employees) on Feb. 10, 2026, from 9 a.m. to 5 p.m. ET. The session will solicit feedback on premarket tobacco product application (PMTA) submissions for electronic nicotine delivery systems (ENDS) products and will be available to view online.
FDA said the roundtable is intended to give small ENDS manufacturers an opportunity to share their experiences with the premarket application process. Topics will include key PMTA components such as product characterization, manufacturing controls, pharmacological profile (including pharmacokinetic studies), studies of adult benefit (including longitudinal cohort and randomized controlled trial studies), and toxicological profile (including estimated lifetime cancer risk).
FDA also established a public docket for comments on the roundtable. Electronic comments must be submitted via Regulations.gov by 11:59 p.m. ET on March 12, 2026 to be considered.
Image source: FDA
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
